| 產(chǎn)品編號(hào) | bs-11804R-BF350 |
| 英文名稱 | Rabbit Anti-ARFGEF2/BF350 Conjugated antibody |
| 中文名稱 | BF350標(biāo)記的二磷酸腺苷核糖基化因子鳥嘌呤核苷酸交換因子2抗體 |
| 別 名 | ADP ribosylation factor guanine nucleotide exchange factor 2 (brefeldin A inhibited); ADP ribosylation factor guanine nucleotide exchange factor 2; ARFGEF 2; ARFGEF2; ARFGEP2; BIG 2; BIG2; Brefeldin A inhibited 2; Brefeldin A inhibited GEP 2; Brefeldin A inhibited guanine nucleotide exchange protein 2; dJ1164I10.1; BIG2_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書 | 100ul |
| 研究領(lǐng)域 | 細(xì)胞生物 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) G蛋白信號(hào) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 202kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human ARFGEF2/BIG2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Guanine nucleotide-exchange proteins (GEPs) accelerate replacement of bound GDP with GTP and thereby activate ADP-ribosylation factors (ARFs), a family of guanine nucleotide-binding proteins that play an important role in intracellular vesicular trafficking. GEPs comprise two major families, large GEPs that are inhibited by brefeldin A (BFA), a protein that effects golgi structure, and a group of smaller GEPs that are insenstive to BFA. Two genes for GEPs found on human chromosomes 8 and 20 encode BFA sensitive GEPs designated BIG1 and BIG2. Both GEPS contain a sec7 domain that is responsible for their brefeldin inhibition and also their catalytic activity. In vivo, BIG1 and BIG2 exist in macromolecular complexes that move between the golgi membranes and cytosol. BIG2 associates with PKA regulatory subunits, implying that BIG2 may act as an A kinase-anchoring protein (AKAP) that could coordinate the cAMP and ARF regulatory pathways. Function: ADP-ribosylation factors (ARFs) play an important role in intracellular vesicular trafficking. ARFGEF2 promotes guanine-nucleotide exchange on ARF1, ARF5 and ARF6 and the activation of ARF1/ARF5/ARF6 through replacement of GDP with GTP. It contains a Sec7 domain, which may be responsible for its guanine-nucleotide exchange activity and also brefeldin A inhibition. Subunit: Homodimer (Probable). Interacts with BIG1; both proteins are probably part of the same or very similar macromolecular complexes. Interacts with PRKAR1A, PRKAR2A, PRKAR1B, PRKAR2B, PPP1CC, PDE3A, TNFRSF1A, MYCBP and EXOC7. Interacts with GABRB1, GABRB2 and GABRB3 Subcellular Location: Cytoplasm. Membrane. Golgi apparatus. Cytoplasm, perinuclear region. Golgi apparatus, trans-Golgi network (By similarity). Endosome (By similarity). Cytoplasm, cytoskeleton, centrosome. Cell projection, dendrite (By similarity). Cytoplasmic vesicle (By similarity). Cell junction, synapse (By similarity). Cytoplasm, cytoskeleton (By similarity). Note=Translocates from cytoplasm to membranes upon cAMP treatment. Localized in recycling endosomes. Tissue Specificity: Expressed in placenta, lung, heart, brain, kidney and pancreas. Post-translational modifications: Phosphorylated upon DNA damage, probably by ATM or ATR. In vitro phosphorylated by PKA reducing its GEF activity and dephosphorylated by phosphatase PP1. DISEASE: Defects in ARFGEF2 are the cause of autosomal recessive periventricular nodular heterotopia type 2 (PVNH2) [MIM:608097]; also known as periventricular heterotopia with microcephaly autosomal recessive. PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH2 is an autosomal recessive form characterized by microcephaly (small brain), severe developmental delay and recurrent infections. No anomalies extrinsic to the central nervous system, such as dysmorphic features or grossly abnormal endocrine or other conditions, are associated with PVNH2. Similarity: Contains 1 SEC7 domain. Database links: Entrez Gene: 10564 Human Entrez Gene: 99371 Mouse Omim: 605371 Human SwissProt: Q9Y6D5 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
